Skip to main content
. 2016 May 26;12(2):771–776. doi: 10.3892/etm.2016.3401

Table V.

Association between survivin expression and prognosis of MM patients treated with FVADT chemotherapy.

Group Cases OS (month) PFS (month)
Survivin-positive group 30 28.65±7.05 19.06±5.04
Survivin-negative group 12 39.67±11.24 35.88±8.25
T-value 6.25 5.87
P-value <0.05 <0.05

Data are presented as the mean ± standard deviation or n. MM, multiple myeloma; FVADT, fludarabine, vincristine, epirubicin, dexamethasone and thalidomide; OS, overall survival; PFS, progression-free survival.